LEANNA GOULD: Open Payments
NPI 1639739451 · NORTON SHORES, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,772 in 103 payments from 29 companies in 2025. Trend: 2023 $1,580 · 2024 $1,486 · 2025 $1,772
Food & beverage: $1,772
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 15 | $192 |
| Novo Nordisk Inc | 12 | $179 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $179 |
| Teva Pharmaceuticals USA, Inc. | 9 | $150 |
| ABBVIE INC. | 10 | $149 |
| Otsuka America Pharmaceutical, Inc. | 6 | $117 |
| Amgen Inc. | 6 | $92 |
| Astellas Pharma US Inc | 4 | $78 |
| PFIZER INC. | 3 | $63 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $53 |
Products named: CAPLYTA, AUSTEDO XR, REXULTI, TRELEGY ELLIPTA, VRAYLAR, Ozempic, Veozah, OTEZLA.
Industry payments across MI — which companies pay providers there.
